HC Wainwright Has Positive Outlook for NextCure Q2 Earnings

NextCure, Inc. (NASDAQ:NXTC) – Analysts at HC Wainwright raised their Q2 2026 EPS estimates for NextCure in a research note issued on Wednesday, July 15th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings per share of ($1.93) for the quarter, up from their prior estimate of ($2.09). HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for NextCure’s current full-year earnings is ($7.89) per share. HC Wainwright also issued estimates for NextCure’s Q3 2026 earnings at ($2.00) EPS, Q4 2026 earnings at ($2.07) EPS, FY2026 earnings at ($7.88) EPS, FY2027 earnings at ($3.33) EPS, FY2028 earnings at ($3.18) EPS and FY2029 earnings at ($2.17) EPS.

NextCure (NASDAQ:NXTC) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.87) earnings per share for the quarter, beating the consensus estimate of ($2.10) by $0.23.

Several other research analysts have also issued reports on the company. Weiss Ratings lowered NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 7th. Wall Street Zen downgraded NextCure from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Zacks Research raised NextCure from a “strong sell” rating to a “hold” rating in a research report on Thursday, June 11th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $19.00.

NextCure Price Performance

Shares of NXTC opened at $5.99 on Friday. The stock has a 50-day moving average of $4.43 and a 200-day moving average of $9.30. The company has a market cap of $21.62 million, a PE ratio of -0.35 and a beta of 1.42. NextCure has a one year low of $1.55 and a one year high of $15.74.

Hedge Funds Weigh In On NextCure

A number of hedge funds have recently added to or reduced their stakes in the stock. Ikarian Capital LLC bought a new stake in NextCure during the 4th quarter worth approximately $3,382,000. Squadron Capital Management LLC bought a new position in shares of NextCure in the fourth quarter valued at approximately $3,363,000. Boothbay Fund Management LLC purchased a new position in shares of NextCure during the fourth quarter valued at approximately $988,000. Affinity Asset Advisors LLC boosted its position in shares of NextCure by 28.9% during the fourth quarter. Affinity Asset Advisors LLC now owns 247,294 shares of the company’s stock valued at $3,509,000 after buying an additional 55,412 shares during the last quarter. Finally, AWM Investment Company Inc. bought a new stake in NextCure during the fourth quarter worth $1,665,000. Institutional investors and hedge funds own 42.65% of the company’s stock.

About NextCure

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.